|
|||||
|
|
Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy |
|
| Authors: | Matthew T. Wheeler Daniel Jacoby Perry M. Elliott Sara Saberi Sheila M. Hegde Neal K. Lakdawala Jonathan Myers Amy J. Sehnert Jay M. Edelberg Wanying Li Iacopo Olivotto |
| Affiliation: | 1. Division of Cardiovascular Medicine, Center for Inherited Cardiovascular Disease, Stanford University, Stanford, CA, USA;2. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, New Haven, CT, USA At the time the study was conducted.;3. University College London & St. Bartholomew's Hospital, London, UK;4. Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA;5. Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA;6. Division of Cardiology, Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA, USA Stanford University, Palo Alto, CA, USA;7. MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, Brisbane, CA, USA;8. MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, Brisbane, CA, USA At the time the study was conducted.;9. Cardiomyopathy Unity, Azienda Ospedaliera Universitaria Careggi and University of Florence, Florence, Italy |
| Abstract: | |
| Keywords: | Beta-blockers Exercise capacity Mavacamten Obstructive hypertrophic cardiomyopathy Symptoms |